Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue
Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

March 30, 2021 Capital Markets and Public M&A

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

 Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

 Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.
April 22, 2024

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024